Anxiety Treatment Statistics in US 2026 | Key Facts

Anxiety Treatment in America 2026

Anxiety disorders remain the most common mental health conditions in the United States, affecting tens of millions of Americans every year — and the demand for treatment has never been more urgent or more visible. According to the National Institute of Mental Health (NIMH), an estimated 19.1% of U.S. adults experienced any anxiety disorder in the past year, representing roughly 48 million people, while a lifetime prevalence of 31.1% means nearly one in three Americans will face an anxiety disorder at some point in their lives. The most recent government data, released by the Substance Abuse and Mental Health Services Administration (SAMHSA) in July 2025 from its landmark 2024 National Survey on Drug Use and Health (NSDUH), marks the first time the survey included a standardized measure of Generalized Anxiety Disorder (GAD) — and the results are striking: 21.7% of U.S. adults reported symptoms of GAD, with 7.4% experiencing moderate or severe symptoms. Among adolescents aged 12 to 17, the numbers are even more alarming, with 41.9% reporting GAD symptoms — over 4 in 10 teens — including 18.8% with moderate or severe symptoms. These figures come from a survey of nearly 70,000 people across all 50 states, making them the most statistically robust snapshot of anxiety in America available today.

Despite the enormous scale of the anxiety crisis, treatment access in the US remains deeply unequal and persistently inadequate. The Centers for Disease Control and Prevention (CDC) reports that in 2024, just 14% of U.S. adults — 1 in 7 — received counseling or therapy from a mental health professional in the past 12 months, while the CDC’s National Center for Health Statistics (NCHS) found that 23.9% received any form of mental health treatment (including medication) as of 2023, up from 19.2% in 2019. The treatment gap is severe: of the estimated 6.8 million Americans with Generalized Anxiety Disorder (GAD), only 43.2% are currently receiving treatment, according to the Anxiety and Depression Association of America (ADAA). More than 122 million Americans lived in a Mental Health Professional Shortage Area (HPSA) as of December 2024, according to the U.S. Health Resources and Services Administration (HRSA). The economic toll of untreated mental illness — anxiety disorders chief among them — is projected to cost the US economy $477.5 billion in 2024 alone, rising to $1.3 trillion by 2040 if left unaddressed, according to a Deloitte and Meharry Global Health analysis. This article compiles the most up-to-date, government-verified statistics on anxiety treatment in the US in 2026 to present a clear, fully cited picture of where the nation stands.

Key Facts & Interesting Statistics: Anxiety Treatment in the US 2026

Source: National Institute of Mental Health (NIMH) — Any Anxiety Disorder Statistics; SAMHSA 2024 NSDUH Annual Report (released July 28, 2025); CDC NCHS NHIS 2024 data; HRSA Designated HPSA Quarterly Report (December 31, 2024); Anxiety and Depression Association of America (ADAA) Facts & Statistics; Deloitte/Meharry School of Global Health — Projected Costs and Economic Impact of Mental Health Inequities in the United States (2024); NAMI Mental Health by the Numbers (updated 2025).

The opening table tells a story of a mental health system under enormous strain. 19.1% of US adults experiencing an anxiety disorder in any given year translates to a figure that surpasses the populations of many entire countries — yet only around 43.2% of those with GAD are in active treatment, pointing to a treatment gap of staggering proportions. The 2024 NSDUH’s first-ever inclusion of a GAD-7 measure adds critical new context: 21.7% of all US adults showed some level of GAD symptoms, and 7.4% had moderate or severe symptoms serious enough to cause daily disruption — numbers that will likely become a baseline for tracking national anxiety trends going forward. The data on adolescents is particularly alarming: 41.9% of US teens aged 12–17 reported GAD symptoms in 2024, with nearly one in five experiencing symptoms of moderate or severe intensity — a finding that underscores the urgency of school-based mental health infrastructure. Meanwhile, the fact that more than 122 million Americans live in areas without enough mental health providers to meet demand explains much of why treatment rates remain so far below the level of need, even as the percentage of adults receiving any mental health treatment has climbed from 19.2% in 2019 to 23.9% in 2023.

Anxiety Disorder Prevalence and Types in the US 2026

Source: National Institute of Mental Health (NIMH) — Any Anxiety Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder, Specific Phobias, and Panic Disorder Statistics pages; SAMHSA 2024 NSDUH Annual Report; Anxiety and Depression Association of America (ADAA) Facts & Statistics.

The range of anxiety disorder subtypes confirms that anxiety is not a single condition but a family of disorders that collectively touch virtually every American in some form. Specific phobias affect the most people in absolute terms — 19.3 million US adults (9.1%) — but Social Anxiety Disorder is arguably the most functionally disruptive, affecting 15 million people and interfering directly with work, relationships, and daily participation in social life. The data on GAD is the most significant new 2024 addition: while the traditional NIMH diagnosed prevalence figure is 3.1% of adults (6.8 million), the 2024 NSDUH’s GAD-7 screening tool found that a far larger 21.7% of adults — roughly 57 million people — reported symptoms consistent with GAD, a number that dwarfs the formal diagnosis rate and underscores the scale of undiagnosed and untreated anxiety in America. The adolescent figures are equally critical: with 31.9% of teens aged 13–18 having a lifetime anxiety disorder and the new NSDUH data showing 41.9% of 12-to-17-year-olds with GAD symptoms, the US is facing what health officials increasingly describe as a youth mental health crisis that will shape anxiety treatment demand in the US for decades to come.

Anxiety Treatment Access and Receipt in the US 2026

Source: CDC NCHS — MMWR QuickStats: Mental Health Treatment Trends, 2019–2023 (published December 2024); CDC Mental Health Conditions & Care page (updated January 2026, 2024 NHIS data); NAMI Mental Health by the Numbers (updated 2025); SAMHSA 2024 NSDUH Detailed Tables; ADAA Facts & Statistics.

The anxiety treatment access data in the US in 2026 presents a picture of incremental but meaningful progress layered over a persistent crisis of unmet need. The CDC’s MMWR QuickStats report (published December 2024) documented that the percentage of adults receiving any mental health treatment climbed from 19.2% in 2019 to 23.9% in 2023 — the most consistent multi-year government trend data available. Most recently, CDC’s 2024 NHIS data shows that 14% of US adults — 1 in 7 — received counseling or therapy in the past 12 months, and this figure was higher in 2024 than in 2023, suggesting the upward momentum is continuing. However, the gap between need and access remains enormous: with approximately 19.1% of adults having a diagnosable anxiety disorder and only around 43.2% of those with GAD in active treatment, the majority of Americans living with anxiety disorders are going without the clinical care that evidence shows works. The disparity is even more stark for young adults: while 49.9% of 18-to-25-year-olds with a mental illness received treatment in 2024, that still leaves roughly half of the most anxiety-affected age group without care. The 50.6% treatment rate for all adults with any mental illness (NAMI, based on 2022–2024 SAMHSA data) is the broadest benchmark — and it means that on any given day, roughly half of all Americans with a diagnosable mental health condition are receiving no treatment whatsoever.

Generalized Anxiety Disorder (GAD) Statistics in the US 2026

Source: National Institute of Mental Health (NIMH) — Generalized Anxiety Disorder Statistics page; SAMHSA 2024 National Survey on Drug Use and Health (NSDUH), released July 28, 2025; Anxiety and Depression Association of America (ADAA).

Generalized Anxiety Disorder occupies a particularly important position in the US anxiety landscape because its 2024 NSDUH data represents the first time the federal government has ever included a validated GAD screening instrument in its flagship behavioral health survey. The results are eye-opening and somewhat alarming in their scale. The traditional NIMH diagnostic figure of 2.7% of adults (~6.8 million) captures only those who meet the full clinical threshold for a GAD diagnosis. But the GAD-7 screening data from the 2024 NSDUH reveals that 21.7% of all US adults — well over one in five — are experiencing some level of GAD symptoms, with 7.4% at moderate or severe intensity where day-to-day functioning is meaningfully impaired. The adolescent data is the most striking single finding in the entire 2024 NSDUH report: 41.9% of American teenagers aged 12–17 reported GAD symptoms, and 18.8% had moderate or severe symptoms — nearly one in five US teens experiencing significant anxiety that would typically warrant clinical attention. The gender disparity adds another layer: female adults are nearly twice as likely as male adults to have a formal GAD diagnosis (3.4% vs. 1.9%), a pattern consistent across virtually all anxiety disorders and one that NIMH attributes to a combination of biological, hormonal, and social risk factors.

Mental Health Workforce Shortage and Its Impact on Anxiety Treatment in the US 2026

Source: Health Resources and Services Administration (HRSA) — Bureau of Health Workforce Projections; HRSA Designated Health Professional Shortage Areas Statistics (December 31, 2025); County Health Rankings & Roadmaps — Mental Health Providers (2025 Annual Data Release, data from 2024); HRSA Behavioral Health Workforce Brief 2023.

The mental health workforce shortage is arguably the single most important structural barrier to anxiety treatment access in the US today, and the numbers from federal data sources are stark. More than 122 million Americans — roughly one in three people in the country — live in a federally designated Mental Health Professional Shortage Area where the ratio of population to providers does not meet the federal threshold for adequate access. To simply remove all existing HPSA designations, the US would need to deploy 8,504 additional psychiatrists immediately, according to HRSA’s own demand modeling. The longer-term projections are even more sobering: to meet projected demand through 2038 — even under current, underutilized service patterns — the US would need 99,840 additional psychologists; addressing the full unmet need would require 136,350 more. On the ground, the situation is felt by patients trying to get appointments: 6 in 10 psychologists do not accept new patients, creating long waitlists for people who have taken the difficult step of seeking help. The one genuinely positive structural development is the sustained expansion of telehealth: from less than 1% of behavioral health visits before 2020 to 40% at the pandemic peak and now a stable, widely adopted modality with 68% of outpatient mental health facilities offering telehealth services as of 2021, a figure that has continued growing. For rural and underserved Americans in shortage areas, telehealth has become the primary pathway to anxiety treatment that geography would otherwise deny them.

Anxiety Disorder Impairment Levels and Demographics in the US 2026

Source: National Institute of Mental Health (NIMH) — Any Anxiety Disorder Statistics (NCS-R data); SAMHSA 2024 NSDUH Annual Report (July 28, 2025); National Alliance on Mental Illness (NAMI) Mental Health by the Numbers (reviewed and updated 2025).

Anxiety disorders impair functioning across a broad spectrum, and the NIMH’s impairment data — drawn from the Sheehan Disability Scale applied to the National Comorbidity Survey Replication — makes clear that even “mild” anxiety should not be dismissed as trivial. The 22.8% with serious impairment represent millions of Americans whose anxiety severely disrupts their ability to work, maintain relationships, and perform daily activities; the 33.7% with moderate impairment experience disruption that meaningfully diminishes their quality of life even if it does not fully prevent participation. The demographic patterns are strikingly consistent across data sources: female adults are consistently nearly twice as likely to experience anxiety disorders as male adults (23.4% vs. 14.3% past-year prevalence); adolescent girls have a lifetime anxiety disorder prevalence of 38.0% compared to 26.1% for boys; and young adults aged 18–25 emerge as the highest-risk adult age group with 32.2% experiencing any mental illness in 2024. The Veterans data — 17.6% with a mental illness and disproportionately high rates of anxiety, PTSD, and depression — represents one of the most underserved populations in the US mental health system, and the 18.1% serious mental illness rate among people experiencing homelessness illustrates how anxiety and other mental health conditions intersect with housing instability in a mutually reinforcing cycle.

Anxiety Treatment Types and Approaches: Statistics in the US 2026

Source: CDC NCHS — National Health Interview Survey (NHIS) 2019–2024; CDC MMWR Mental Health Treatment Trends 2019–2023 (December 2024); CDC Mental Health Conditions & Care page (January 2026); NIMH — Anxiety Disorders treatment overview; PMC — High Out-of-Pocket Cost Burden of Mental Health Care (Psychiatric Services, published February 2025, based on MEPS 2018–2021).

The treatment landscape for anxiety disorders in the US in 2026 is shaped by three intersecting trends: rising prescription medication use, steadily growing therapy uptake, and the now-permanent integration of telehealth into the behavioral health system. On the medication side, SSRIs have displaced benzodiazepines as the standard pharmacological first-line treatment for most anxiety disorders, including GAD, social anxiety, and panic disorder, owing to their superior safety profile for long-term use and proven efficacy across comorbid anxiety and depressive symptoms. The percentage of adults taking prescription medication for mental health rose from 15.8% in 2019 to 16.5% in 2020 and has continued its gradual upward trend. Meanwhile, counseling and therapy rates have seen stronger growth: the 14% of adults receiving therapy in 2024 represents a meaningful increase from the 9.5% baseline in 2019, with the CDC noting this rate was higher in 2024 than in 2023 — a trend CDC directly links to reduced stigma, telehealth accessibility, and greater insurance coverage awareness. Despite this progress, cost remains a significant barrier: among psychiatric outpatients living below the federal poverty level, 12.8% faced a high out-of-pocket cost burden (defined as spending 10% or more of disposable family income on mental health care), according to research published in Psychiatric Services in February 2025 using federal Medical Expenditure Panel Survey data.

Economic Impact of Anxiety Disorders and Treatment Gaps in the US 2026

Source: Deloitte and Meharry School of Global Health — “The Projected Costs and Economic Impact of Mental Health Inequities in the United States” (May 2024); National Alliance on Mental Illness (NAMI) Mental Health by the Numbers (reviewed 2025); WHO Mental Health Atlas 2024 and World Mental Health Today Report (September 2025); Anxiety Disorders in the 21st Century — AJMC.

The economic impact of anxiety disorders and broader mental health conditions in the US is one of the most compelling — and least discussed — arguments for dramatically expanding treatment access and funding. The Deloitte/Meharry analysis, the most comprehensive recent US-specific economic study, found that untreated mental illness will cost the US $477.5 billion in 2024 — approximately 1.7% of the entire US GDP — and that the cumulative cost from 2024 through 2040 will reach $14 trillion if current patterns of undertreatment persist. Critically, these costs are not primarily driven by the direct cost of mental health care itself; rather, the vast majority — consistent with the broader literature showing that more than 75% of anxiety disorder costs are indirect — comes from lost workforce productivity, absenteeism, presenteeism, disability, and premature death. The $193.2 billion in lost annual earnings attributable to serious mental illness (NAMI) is a figure that dwarfs what the US currently spends on mental health treatment itself. On the global stage, the WHO’s Mental Health Atlas 2024 report (released September 2025) confirmed that anxiety and depression alone cost the world $1 trillion each year in lost productivity — a figure that has not changed significantly despite decades of awareness campaigns, reinforcing the conclusion that awareness alone, without dramatic treatment access expansion, does not close the economic gap.

Mental Health Treatment Among Young Adults and Adolescents: Anxiety in the US 2026

Source: NIMH — Any Anxiety Disorder Statistics (NCS-A data for adolescents); SAMHSA 2024 NSDUH Annual Report (July 28, 2025); NAMI Mental Health by the Numbers (updated 2025); CDC Youth Risk Behavior Surveillance System (YRBS) 2023; The Trevor Project 2023 National Survey.

The youth and young adult anxiety data represent perhaps the most urgent dimension of the entire US anxiety treatment picture in 2026. The convergence of multiple data streams — NIMH’s lifetime prevalence figures, the landmark 2024 NSDUH GAD measurements, the CDC’s YRBS findings on teen depression, and SAMHSA’s treatment access data — collectively paints a picture of a generation experiencing anxiety at rates that have no precedent in comparable survey data. NIMH data shows 31.9% of adolescents aged 13–18 have a lifetime anxiety disorder, with 38.0% of girls affected — a figure that would have been considered extraordinary in any prior era of mental health research. The 2024 NSDUH’s revelation that 41.9% of US teens experience GAD symptoms, including nearly one in five at moderate or severe levels, is arguably the single most important new data point released in the entire 2025 mental health data cycle. There are two genuine bright spots in the youth data: adolescent serious suicide ideation dropped from 12.9% in 2021 to 10.1% in 2024, and adolescent major depressive episodes declined from 20.8% to 15.4% over the same period, according to SAMHSA — suggesting that targeted youth mental health interventions are having some impact. However, with NIMH noting that half of all lifetime mental illness begins by age 14 and 75% by age 24, the window for early intervention is both narrow and critically important for shaping a lifetime of mental health outcomes.

Disclaimer: The data reports published on The Global Files are sourced from publicly available materials considered reliable. While efforts are made to ensure accuracy, no guarantees are provided regarding completeness or reliability. The Global Files is not liable for any errors, omissions, or damages resulting from the use of these reports.